Navidea Biopharma (NAVB) Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Navidea Biopharma (NAVB) Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent

Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent

May 11, 2021 7:30 AM EDT

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the granting of a National Institutes of Health (NIH) award to the University of California San Diego School of Medicine for the proposal entitled, Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept. The award (Project Number: 1R01DK127201-01), from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, was granted to Co-Principal Investigators UC San Diego faculty Carl Hoh, MD and... More